AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00834249 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Venlafaxine 25 mg Tablets
Description: 1 x 25 mg, single-dose fasting
Study NCT04046302 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dinoprostone
Description: 1 vaginal tablet of dinoprostone (3mg) (prostin® E2, Pharmacia \& Upjohn, Puurs, Belgium) self-inserted by participants 3 hours before scheduled IUD insertion appointment.
Study NCT04046302 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: one tablet of placebo self-inserted by participants 3 hours before scheduled IUD insertion appointment.
Study NCT05220150 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: FFC-MRI scan
Description: Undergo one FFC-MRI scan.
Study NCT05220150 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: FFC-MRI scan
Description: Undergo one FFC-MRI scan.
Study NCT01870635 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ondansetron
Description: Eligible children will receive one weight based (0.13 - 0.26 mg/kg) dose of an oral ondansetron disintegrating tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
Study NCT01870635 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Eligible children will receive one dose of an oral disintegrating Placebo (sugar pill) tablet. Subsequent therapy will be in accordance with World Health Organization guidelines as dictated by the child's hydration status.
Study NCT03102684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Secondhand exposure to e-cigarette aerosols (low)
Description: Participants will be exposed to secondhand aerosols produced by e-cigarette use. E-cigarette with low resistance will be used by an experienced smoker (tobacco flavor liquid, 12 mg nicotine, 4 sec puffs, 20-30 seconds inter-puff interval). Duration of exposure: 30 minutes.~All study subjects will participate in this arm as the study has a cross-over design.
Study NCT03102684 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Secondhand exposure to e-cigarette aerosols (high)
Description: Participants will be exposed to secondhand aerosols produced by e-cigarette use. E-cigarette with high resistance will be used by an experienced smoker (tobacco flavor liquid, 12 mg nicotine, 4 sec puffs, 20-30 seconds inter-puff interval). Duration of exposure: 30 minutes.~All study subjects will participate in this arm as the study has a cross-over design.
Study NCT04554368 — intervention group
Intervention type: PROCEDURE
Intervention: intra-arterial contrast enhanced Flat Detector CT
Description: After femoral artery puncture, FDCT scan (if necessary) and IA-CEFDCT scan were performed on a single flat-detector angiography system (Allura Xper FD20, Philips Medical systems, Best, the Netherlands), respectively. FDCT was acquired with the following acquisition parameters: 20s rotation, 220° rotation, 617 single frames at a frame rate of 30/s, 48cm detector field of view, 1024 acquisition matrix. Images were reconstructed using a soft-tissue kernel with an isotropic voxel size of 0.9 × 0.9 × 0.9 mm on a dedicated workstation for FPCT data (XperCT Dual 3.2.0). For image analysis, these isotropic FDCT data were viewed in the axial plane with 5 mm slice thickness.
Study NCT01334073 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Axitinib plus everolimus
Description: Patients will take both drugs orally, every day, without planned rest period (AX bid and EV once a day). By convention one cycle is 28 days. At the first cycle patients will take one week of AX single agent before starting EV. Patients will be treated at increasing dose levels (DLs) in successive cohorts of 3-6 patients according to the number of patients with dose limiting toxicities (DLT) until the maximum tolerated dose
Study NCT01053676 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lanthanum Carbonate (Fosrenol, BAY77-1931) Granule
Description: BAY77-1931 Granule TID for 4 days
Study NCT01053676 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lanthanum Carbonate (Fosrenol, BAY77-1931) Chewable tablet
Description: BAY77-1931 Chewable tablet TID for 4 days
Study NCT01723306 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: Gene Modified T Cells
Description: Subjects will undergo T cell leukopheresis. The collected T cells will be genetically modified, and then re-infused peripherally. IL2 will be given concomitantly for 30 days post modified T cell infusion via CADD pump.
Study NCT02302911 — intervention group
Intervention type: BEHAVIORAL
Intervention: Early intensive behavioral intervention
Description: at least 10 hours a week of early intensive behavioral intervention
Study NCT02302911 — intervention group
Intervention type: BEHAVIORAL
Intervention: Early intensive eclectic intervention
Description: at least 10 hours a week of early intensive eclectic intervention
Study NCT02302911 — intervention group
Intervention type: OTHER
Intervention: Treatment as usual
Description: receipt of any Intervention that is less intensive than 10 hours a week
Study NCT03950986 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Modified clinical reminders
Description: Clinical reminders for the vaccines of interest will be bundled into a single reminder, and other changes made to streamline the design and reduce provider burden. Other changes include an immunization dashboard that relays a patient's vaccination status and talking points for providers to use in their dialogues with patients.
Study NCT00661375 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nexavar (Sorafenib, BAY43-9006)
Description: BAY 43-9006 400mg b.i.d. Treatment will continue until progression of underlying disease, unacceptable toxicity whose causal relationship to the study drug cannot be ruled out and which requires discontinuation of the drug, or consent withdrawal.
Study NCT03607227 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levobupivacaine
Description: Active substance. Levobupivacaine 3.75 mg/ml 15 ml is given as a bolus injection at start of surgery, followed by ropivacaine 2 mg/ml continous infusion 5-8 ml/h from the end of surgery until end of intervention at the fourth to seventh postoperative day.
Study NCT03607227 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline Solution
Description: Placebo. Saline solution (NaCl 0.9%) is given in equivalent intervals and doses as the active substances.
Study NCT03734510 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Supplement: hesperidin and flaxseed
Description: 2 capsules hesperidin and 30 g flaxseed
Study NCT03734510 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Supplement: hesperidin
Description: 2 capsules hesperidin
Study NCT03734510 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Dietary Supplement: flaxseed
Description: 30 g flaxseed
Study NCT03734510 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: control
Description: no supplementation
Study NCT02603523 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Senior Dance
Description: The Senior Dance classes consist of different choreographies, which include rhythmic and simple movements with rhythmic folk songs. During the classes, participants can practice the movements sitting or standing, quickly or slowly, in circles, individually, in pairs or in small groups. The concentration required to learn the choreographies challenges balance, motor coordination and cognitive function.
Study NCT02822365 — intervention group
Intervention type: PROCEDURE
Intervention: Computed Tomography
Description: Undergo PET/CT scan as clinically indicated (Note: CT is for attenuation correction and not for diagnostic purposes).
Study NCT02822365 — intervention group
Intervention type: DEVICE
Intervention: Imaging Phantoms
Description: Undergo limited field of view PET scan with the Pocket Phantom placed nearby to assist in scanner calibration. No additional PET tracer will be used.
Study NCT02822365 — intervention group
Intervention type: PROCEDURE
Intervention: Positron Emission Tomography
Description: Undergo PET/CT scan as clinically indicated.
Study NCT04763525 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Pythagorean Self-Awareness Intervention(PSAI)
Description: The PSAI is a mental, stress-management technique that promotes self-awareness, cognitive reconstruction and self-improvement based on the Golden Verses moral framework of the ancient Greek philosopher Pythagoras. The individual must practice the technique twice daily( at bed-time and in the morning, every day, at home) and through a 3-stage internal dialogue (recall of daily events, inspection of related thoughts and emotions and self-appraisal)is encouraged to detect wrong choices and unhealthy behaviours and initiate self-correction towards a healthier lifestyle.
Study NCT04228419 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Total Shoulder Arthroplasty
Description: Replacement of the shoulder joint (ball and socket, or humeral head and glenoid) using prosthetic components.
Study NCT04228419 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Reverse Shoulder Arthroplasty
Description: Replacement of the shoulder joint like the TSA, however the orientation of the ball and socket is reversed.
Study NCT01774942 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Procedure/Surgery
Description: All teeth were extracted and replaced by a set of provisional full dentures in upper and lower jaws. Three months after extractions, dental implants were surgically placed and mucosa sutured over them. Three monts later, the dentures were re-lined and fitted onto the implants. Blood draw done by phlebotomist.
Study NCT02039947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dabrafenib
Description: Dabrafenib will be provided as 50 mg and 75 mg capsules
Study NCT02039947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Trametinib
Description: Trametinib will be provided as 0.5 mg and 2.0 mg tablets
Study NCT02802475 — intervention group
Intervention type: BIOLOGICAL
Intervention: vena punction
Study NCT03893214 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: virtual reality exposure for acrophobia
Description: The setting of the virtual reality is the Gasometer Oberhausen, Europe's largest disc-type gas container which is one of the most famous high buildings in the area. After a baseline phase, participants will undergo a gradual exposure. Participants will first look up to the building and then be guided upstairs to have an exposure phase on 11 floors. On the highest floor they will walk around a gallery. In the end, there will be a recovery phase.
Study NCT03893214 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: virtual reality exposure for acrophobia
Description: The setting of the virtual reality is the Gasometer Oberhausen, Europe's largest disc-type gas container which is one of the most famous high buildings in the area. After a baseline phase, participants will undergo a gradual exposure. Participants will first look up to the building and then be guided upstairs to have an exposure phase on 11 floors. On the highest floor they will walk around a gallery. In the end, there will be a recovery phase.
Study NCT03893214 — intervention group
Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: movie
Description: Participants will watch a movie without height content for the same amount of time as the virtual reality exposure will need.
Study NCT03434366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine and dexmedetomidine
Description: intranasal ketamine and dexmedetomidine for treatment for autism spectrum disorder
Study NCT03434366 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ketamine
Description: intranasal ketamine for treatment for autism spectrum disorder
Study NCT03434366 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: intranasal saline for treatment for autism spectrum disorder
Study NCT00977561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: figitumumab
Description: Figitumumab (20 mg/kg)
Study NCT00977561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin (Or Carboplatin)
Description: Cisplatin (75 mg/m2 IV on Day 1) or Carboplatin AUC 5
Study NCT00977561 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: Etoposide (100 mg/m2 IV on Days 1, 2 and 3)
Study NCT00977561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cisplatin (Or Carboplatin)
Description: Cisplatin (75 mg/m2 IV on Day 1) or Carboplatin AUC 5
Study NCT00977561 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Etoposide
Description: Etoposide (100 mg/m2 IV on Days 1, 2 and 3)
Study NCT01873833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: Given PO
Study NCT01873833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: Given PO
Study NCT01873833 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lapatinib ditosylate
Description: Given PO
Study NCT01873833 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: Given IV
Study NCT01873833 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT03264950 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Elastography
Description: an ultrasound exam after selecting the best acoustic window, a region of interest (ROI) is placed in an area of the liver perpendicular to the liver capsule, taking care not to include large vasculature or biliary structures.~Similarly an acoustic window will be selected for the pancreas as well
Study NCT00927082 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: peginterferon alfa-2a [Pegasys]
Description: 90 or 180 micrograms/week sc for 24 or 48 weeks in original study (WV19432). No study treatment in long-term post-treatment follow-up study (MV22430)
Study NCT02475837 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vorapaxar sulfate
Description: The study drug (12-week supply of study drug) will be dispensed to enrolled patients on the first day following surgery.
Study NCT02475837 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: The placebo will match the study drug, vorapaxar sulfate, in appearance. A 12-week supply will be dispensed to enrolled patients on the first day following surgery.
Study NCT00644267 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Telemedicine
Description: Telemedicine reporting of blood pressure, weight, physical activity
Study NCT00644267 — intervention group
Intervention type: BEHAVIORAL
Group type: NO_INTERVENTION
Intervention: Telemedicine
Description: Telemedicine reporting of blood pressure, weight, physical activity
Study NCT00551356 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin lispro mix 25
Description: Insulin lispro mix 25 given SC twice-daily in conjunction with oral antidiabetic medications.
Study NCT00551356 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine
Description: Insulin glargine given SC once-daily in conjunction with oral antidiabetic medications.
Study NCT02006654 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Once daily, matching placebo capsules, orally
Study NCT02006654 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idalopirdine
Description: Once daily, encapsulated tablets, orally
Study NCT03176199 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxycodone
Description: Every 12 hours for control-released oxycodone (OxyContin®)
Study NCT03176199 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oxycodone
Description: Every 6 hours for immediate-released oxycodone (OxyNorm®)
Study NCT02198144 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: barbershop-based BP measurement
Description: BP Measurements and blood pressure reducing medication
Study NCT03384043 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Smartphone Personal Assistant
Description: Electronic memory aids (e.g., pagers) are known to support memory for goals and intentions (prospective memory) in individuals with cognitive impairment. Smartphone technology has the potential to enhance the benefits of previous electronic memory aids because they can provide reminders not only at the correct time, but also at the correct location.
Study NCT03384043 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Implementation Intention
Description: Verbally specifying when and where one intends to complete a goal or action (prospective memory) is known to improve the likelihood of later completing that prospective memory. The implementation intention is the best known memory strategy for prospective memory in patients with mild cognitive impairment.
Study NCT01420575 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Visual Decision Aid and Shared Decision Making Model
Description: Visual aid is a graph showing the average weight of patients who take olanzapine versus perphenazine over the course of 18 months. A script explaining the information on the graph, accompanies the graph. Patient may decide to stay on current dose of olanzapine, or be tapered off and prescribed a dose of perphenazine based on current symptoms and tolerability. Perphenazine (4-8mg ORALLY 3 times a day) will be used.
Study NCT02823561 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Garcinia mangostana
Study NCT02823561 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Control group
Study NCT00769405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil
Description: Given IV
Study NCT00769405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: leucovorin calcium
Description: Given IV
Study NCT00769405 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oxaliplatin
Description: Given during surgery
Study NCT01420575 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Usual care is standard clinical discussion and advice from a psychiatrist. Patient may decide to stay on current dose of olanzapine, or be tapered off and prescribed a dose of perphenazine based on current symptoms and tolerability. Perphenazine (4-8mg ORALLY 3 times a day) will be used.
Study NCT01874483 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: placebo
Study NCT00769405 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: hyperthermia treatment
Description: Given intraperitoneally during surgery
Study NCT01874483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 187004
Description: BI 187004, dose 2
Study NCT01874483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 187004
Description: BI 187004, dose 4
Study NCT01874483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 187004
Description: BI 187004, dose 5
Study NCT01874483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 187004
Description: BI 187004, dose 6
Study NCT01874483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 187004
Description: BI 187004, dose 7
Study NCT01874483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 187004
Description: BI 187004, dose 1
Study NCT01874483 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BI 187004
Description: BI 187004, dose 3
Study NCT03364218 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-Acetyl Cysteine
Description: Nebulized N-Acetyl Cysteine administered every 12 hours
Study NCT03850106 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT03850106 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Indus810
Description: Active product
Study NCT02523638 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Pegylated-Proline-Interferon alpha-2b in a Pre-filled Pen
Description: Subjects will continue to receive the dosage which delivers the optimal disease response (hematocrit \[Hct\]\<45%, platelets \[PLTs\]\<400 x 109/L and leukocytes \[WBCs\]\<10 x 109/L), as determined in the PROUD-PV study, preferably at the level of target blood values.
Study NCT03846232 — intervention group
Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study NCT02451735 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video and Booklet
Description: Printed and DVD materials about Genetic Counseling. Self-reported feedback will be collected and reviewed to compare to the control group response.
Study NCT02451735 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Factsheet
Description: Patient factsheet about Genetic Counseling. Self-reported feedback will be collected and reviewed to compare to the intervention group response.
Study NCT04149353 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: PET/MR
Description: Patient will be scheduled for a pre-treatment PET/MR and proceed to neoadjuvant chemotherapy per the direction of the medical oncologist. Within four weeks after completion of chemotherapy the patient will undergo a post-treatment PET/MR, and proceed for curative intent surgery if they are still surgical candidates.
Study NCT00945620 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: ropivicaine
Description: 30mL containing 300mg ropivicaine 1% with addition of 1:300,000 epinepherine
Study NCT00945620 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Placebo